{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Arbaclofen+Placarbil", "query": { "intervention": "Arbaclofen Placarbil" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 20, "total_pages": 2, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Arbaclofen+Placarbil&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-20T23:48:34.741Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00978016", "title": "A Study to Evaluate the Efficacy and Safety of Arbaclofen Placarbil (XP19986) as Adjunctive Therapy in Subjects With Gastroesophageal Reflux Disease (GERD)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Gastroesophageal Reflux Disease" ], "interventions": [ { "name": "arbaclofen placarbil-Cohort 1", "type": "DRUG" }, { "name": "Placebo-Cohort 5", "type": "DRUG" }, { "name": "arbaclofen placarbil-Cohort 2", "type": "DRUG" }, { "name": "arbaclofen placarbil-Cohort 3", "type": "DRUG" }, { "name": "arbaclofen placarbil-Cohort 4", "type": "DRUG" }, { "name": "PPI", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "XenoPort, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 460, "start_date": "2009-09", "completion_date": "2010-12", "has_results": false, "last_update_posted_date": "2021-02-21", "last_synced_at": "2026-09-20T23:48:34.741Z", "location_count": 62, "location_summary": "Huntsville, Alabama • Chandler, Arizona • Mesa, Arizona + 56 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "Chandler", "state": "Arizona" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT00978016" }, { "nct_id": "NCT03319732", "title": "A Study to Evaluate the Long-term Safety of Arbaclofen Extended-Release Tablets for Patients With Spasticity Due to MS", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Multiple Sclerosis", "Spasticity, Muscle" ], "interventions": [ { "name": "Arbaclofen", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "RVL Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 323, "start_date": "2018-04-03", "completion_date": "2020-06-11", "has_results": true, "last_update_posted_date": "2022-08-09", "last_synced_at": "2026-09-20T23:48:34.741Z", "location_count": 1, "location_summary": "Fresno, California", "locations": [ { "city": "Fresno", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03319732" }, { "nct_id": "NCT01844232", "title": "One Year, Open Label, Dose Escalation Long-term Safety Study in Multiple Sclerosis (MS) Subjects With Spasticity", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Multiple Sclerosis", "Spasticity" ], "interventions": [ { "name": "arbaclofen", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "RVL Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 150, "start_date": "2013-04", "completion_date": "2015-01", "has_results": false, "last_update_posted_date": "2022-04-25", "last_synced_at": "2026-09-20T23:48:34.741Z", "location_count": 21, "location_summary": "Gilbert, Arizona • Phoenix, Arizona • Pasadena, California + 17 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Pasadena", "state": "California" }, { "city": "Torrance", "state": "California" }, { "city": "Torrance", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01844232" }, { "nct_id": "NCT01013480", "title": "An Open Label Extension Study of STX209 in Subjects With Fragile X Syndrome", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Fragile X Syndrome" ], "interventions": [ { "name": "Arbaclofen", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Seaside Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Years", "maximum_age": "40 Years", "sex": "ALL", "summary": "6 Years to 40 Years" }, "enrollment_count": 45, "start_date": "2009-11", "completion_date": "2012-12", "has_results": false, "last_update_posted_date": "2012-12-20", "last_synced_at": "2026-09-20T23:48:34.741Z", "location_count": 9, "location_summary": "Los Angeles, California • Sacramento, California • Chicago, Illinois + 6 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Staten Island", "state": "New York" }, { "city": "Chapel Hill", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT01013480" }, { "nct_id": "NCT01325220", "title": "Efficacy and Safety Study of STX209 (Arbaclofen) for the Treatment of Social Withdrawal in Children With Fragile X Syndrome", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Fragile X Syndrome" ], "interventions": [ { "name": "arbaclofen", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Seaside Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "5 Years", "maximum_age": "11 Years", "sex": "ALL", "summary": "5 Years to 11 Years" }, "enrollment_count": 172, "start_date": "2011-06", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-07-31", "last_synced_at": "2026-09-20T23:48:34.741Z", "location_count": 28, "location_summary": "Phoenix, Arizona • Long Beach, California • Sacramento, California + 24 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Long Beach", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT01325220" }, { "nct_id": "NCT01172509", "title": "TMS Measures of Plasticity and Excitatory/Inhibitory Ratio as Biomarkers: R-baclofen Effects in Normal Volunteers", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Autism" ], "interventions": [ { "name": "R-baclofen", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gonzalez-Heydrich, Joseph, M.D.", "sponsor_class": "INDIV", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "30 Years", "sex": "ALL", "summary": "18 Years to 30 Years" }, "enrollment_count": 6, "start_date": "2010-10", "completion_date": "2012-07", "has_results": false, "last_update_posted_date": "2015-08-21", "last_synced_at": "2026-09-20T23:48:34.741Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT01172509" }, { "nct_id": "NCT01743651", "title": "Efficacy Study of Arbaclofen to Treat Spasticity in Multiple Sclerosis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Spasticity", "Multiple Sclerosis" ], "interventions": [ { "name": "arbaclofen", "type": "DRUG" }, { "name": "baclofen", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "RVL Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 353, "start_date": "2012-11", "completion_date": "2014-04", "has_results": false, "last_update_posted_date": "2022-04-25", "last_synced_at": "2026-09-20T23:48:34.741Z", "location_count": 25, "location_summary": "Cullman, Alabama • Long Beach, California • Aurora, Colorado + 20 more", "locations": [ { "city": "Cullman", "state": "Alabama" }, { "city": "Long Beach", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Bradenton", "state": "Florida" }, { "city": "Maitland", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01743651" }, { "nct_id": "NCT00817986", "title": "A Study to Evaluate the Safety and Tolerability of Arbaclofen Placarbil (XP19986) in Subjects With Acute Back Spasms", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Back Pain" ], "interventions": [ { "name": "Arbaclofen placarbil, 20 mg", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Arbaclofen placarbil, 30 mg", "type": "DRUG" }, { "name": "Arbaclofen placarbil, 40 mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "XenoPort, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 161, "start_date": "2008-12", "completion_date": "2009-07", "has_results": false, "last_update_posted_date": "2021-02-21", "last_synced_at": "2026-09-20T23:48:34.741Z", "location_count": 20, "location_summary": "Litchfield Park, Arizona • Anaheim, California • San Diego, California + 16 more", "locations": [ { "city": "Litchfield Park", "state": "Arizona" }, { "city": "Anaheim", "state": "California" }, { "city": "Anaheim", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Vista", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00817986" }, { "nct_id": "NCT01282268", "title": "Efficacy and Safety Study of STX209 (Arbaclofen) for Social Withdrawal in Adolescents and Adults With Fragile X Syndrome", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Fragile X Syndrome" ], "interventions": [ { "name": "arbaclofen", "type": "DRUG" }, { "name": "placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Seaside Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "12 Years to 50 Years" }, "enrollment_count": 125, "start_date": "2011-05", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-07-31", "last_synced_at": "2026-09-20T23:48:34.741Z", "location_count": 24, "location_summary": "Phoenix, Arizona • Long Beach, California • Sacramento, California + 20 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Long Beach", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT01282268" }, { "nct_id": "NCT01555333", "title": "An Open Label Extension Study in Subjects With Fragile X Syndrome", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Fragile X Syndrome" ], "interventions": [ { "name": "arbaclofen", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Seaside Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "5 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "5 Years to 50 Years" }, "enrollment_count": 357, "start_date": "2011-11", "completion_date": "2013-07", "has_results": false, "last_update_posted_date": "2013-07-31", "last_synced_at": "2026-09-20T23:48:34.741Z", "location_count": 23, "location_summary": "Phoenix, Arizona • Long Beach, California • Sacramento, California + 20 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Long Beach", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01555333" } ] }